ABIVAX is a French biotech with a novel ulcerative colitis treatment in phase 3 trials. Click here to find out why I am ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from a late-stage study on next-generation obesity drug, CagriSema. Top-line ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

“This is a significant milestone for our efforts to advance medicines for IBD using insights from our proprietary 3D human tiss Today Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg ...

Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against mpox with 84% ...

Odds for desensitization and remission fell as patients missed consecutive doses of peanut oral immunotherapy, according to a ...

The Business Research Company's Comprehensive Insights Of The Global Omvoh Market: Key Drivers, Trends, Growth Opportunities, And Forecast For 2025-2034 It will grow ...

This article covers topics such as side effects, dosage, and how Simponi works. Simponi is a biologic and belongs to a drug class called tumor necrosis factor (TNF) blockers. The medication is not ...

Other significant developments include promising phase 3 trial results for alopecia areata and the FDA's approval of Omvoh, which, along with solid earnings, position the company favorably even as ...